



Attorney Docket No. 5470-401

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Stafford et al.
Application No.: 10/573,131
Filed: April 18, 2006

Confirmation No.: 4529

Group Art Unit: 1634

Examiner: J. Sitton

For: *METHODS AND COMPOSITIONS FOR THE CORRELATION OF SINGLE
NUCLEOTIDE POLYMORPHISMS IN THE VITAMIN K EPOXIDE REDUCTASE
GENE AND WARFARIN DOSAGE*

Date: May 10, 2007

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §1.97(b)**

Sir:

Attached is a list of documents, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

Respectfully submitted,


Mary L. Miller
Mary L. Miller
Registration No. 39,303

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

"Express Mail" mailing label number: EV 854928696 US ; Date of Deposit: May10, 2007

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Evelyn Casey
Evelyn Casey

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
		Application Number		10/573,131	
		Filing Date		April 18, 2006	
		First Named Inventor		Darrel W. Stafford	
		Group Art Unit		1634	
Examiner Name		J. Sitton			
Attorney Docket Number		5470-401			
Sheet	1 of 1				

U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known[see 1])		
		US-			

U.S. PATENT APPLICATIONS

Examiner Initials*	Cite No.	U.S. Serial No.	Name of Applicant of Cited Document	Date of Filing of Cited Document MM-DD-YYYY
		US-		
		US-		
		US-		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	Aithal et al. "Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications" <i>The Lancet</i> 353(9154):717-719 (1999)	
	2.	Cheung et al. "Localization of a Metal-Dependent Epitope to the Amino Terminal Residues 33-40 of Human Factor IX" <i>Thrombosis Research</i> 80(2):419-427 (1995)	
	3.	Davis et al. "A quantum chemical study of the mechanism of action of Vitamin K carboxylase (VKC) III. Intermediates and transition states" <i>Journal of Molecular Graphics and Modelling</i> (November 6, 2006), [Epub ahead of print]	
	4.	Davis et al. "A quantum chemical study of the mechanism of action of Vitamin K epoxide reductase (VKOR) II. Transition states" <i>Journal of Molecular Graphics and Modelling</i> (November 6, 2006), [Epub ahead of print]	
	5.	Herlitschka et al. "Overexpression of Human Prothrombin in Permanent Cell Lines Using a Dominant Selection/Amplification Fusion Marker" <i>Protein Expression and Purification</i> 8:358-364 (1996)	
	6.	Oldenburg et al. "Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1): The Key Protein of the Vitamin K Cycle" <i>Antioxidants & Redox Signaling</i> 8(3 & 4):347-353 (2006)	
	7.	Rettie et al. "A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin" <i>Epilepsy Research</i> 35: 253-255 (1999)	
	8.	Schmidt-Krey et al. "Two-dimensional crystallization of human vitamin K-dependent γ-glutamyl carboxylase" <i>Journal of Structural Biology</i> 157:437-442 (2007)	
	9.	Takahashi et al. "Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients" <i>Clinical Pharmacology & Therapeutics</i> 73(3):253-263 (2003)	
	10.	Wallin et al. "Warfarin and the Vitamin K-Dependent γ-Carboxylation System" <i>TRENDS in Molecular Medicine</i> 10(7):299-302 (2004)	
	11.	Wallin et al. "Vitamin K 2,3-epoxide reductase and the vitamin K-dependent γ-carboxylation system" <i>Thrombosis Research</i> 108:221-226 (2003)	
	12.	Wu et al. "Cloning and expression of the cDNA for human gamma-glutamyl carboxylase" <i>Science</i> 254(5038):1634-1636 (1991)	
	13.	Xie et al. "CYP2C9 allelic variants: ethnic distribution and functional significance" <i>Advanced Drug Delivery Reviews</i> 54: 1257-1270 (2002)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.